インサイト
当社は航空衛星通信アンテナから体内埋め込みのバイオセンサー、脱炭素化の熱力学からAIを活用したバイオ工学まで、ディープテックの活用で現状を打破して変化を生み出しています。
最新の研究成果とインサイトをご紹介し、いま騒がれているイノベーションの先には何があるか、新しいテクノロジーがどのように重要なビジネス上の課題を解決しているかを解説します。
Genomics, panomics and long read sequencing for better patient care
Symon Cotton has been reflecting on the future of the genomics ecosystem. Here he discusses how genomics – plus the emergence of panomics and long read sequencing – could inform clinical practice and patient care ...
O-RAN and AI: ready to transform service performance in the optimised network（O-RANとAIによるネットワーク最適化でサービスパフォーマンスが変革）」
In our O-RAN white paper, we explore how the O-RAN RIC and AI can automate network optimisation, overcoming network complexity and deliver high-performance services ...
ライフサイエンスにおける量子センシングの可能性
弊社は量子センシング技術のリーダーであるスイスのQnami社から、バイオメディカル分野においてNV磁力計が臨床的価値を提供し、新たなビジネスを生み出す可能性のあるアプリケーションを特定するよう依頼されました。
Autonomy for US Government organizations is within reach
Advances in automation have enabled transformative opportunities for federal defense. Now is the time to seize them ...
Valuable opportunity for the autonomous electricity grid
In this insight piece, Gavin Doyle explores the opportunities and technical challenges of an autonomous power grid and unpacks the three key enablers of such an advance ...
Smart Grid – Electrical Review
Technology strategist Gavin Doyle explores the opportunities and technical challenges associated with the autonomous electrical power grid and unpacks what he sees as the three key enablers of such an advance: automation (naturally), decentralisation, and data connectivity ...
What next for precision medicine?
The world of DNA testing is changing fast and the race is on to provide cheap, quick genetic diagnoses for patients. Symon Cotton, Head of Life Sciences takes a look at the opportunities on offer for companies working in this ...
When will quantum technology deliver commercially relevant results?
The excitement around quantum technology is tempered by some pretty formidable factors. Not only is it expensive, but it can also be difficult to predict when it will start to deliver commercially relevant results ...
